CD19-directed Chimeric Antigen Receptor [EPC] - N0000193546

Pharmacologic Code	N0000193546
Pharmacologic Name	CD19-directed Chimeric Antigen Receptor
Pharmacologic Uses	CD19-directed genetically modified autologous T-cells
Pharmacologic Concept	Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description	An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions: A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication. A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

The table contains 3 products whose active ingredient are classified under the same pharmacologic class CD19-directed Chimeric Antigen Receptor [EPC].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0078-0846	Kymriah	Non-Proprietary Name: Tisagenlecleucel	Injection, Suspension	Intravenous	Novartis Pharmaceuticals Corporation	ACTIVE
	0078-0958	Kymriah	Non-Proprietary Name: Tisagenlecleucel	Injection, Suspension	Intravenous	Novartis Pharmaceuticals Corporation	ACTIVE
	71287-119	Yescarta	Non-Proprietary Name: Axicabtagene Ciloleucel	Suspension	Intravenous	Kite Pharma, Inc.	ACTIVE